The workshop included presentations from public and private sector experts on various factors involved in bringing new sickle cell disease therapies to market, including the pathophysiology of sickle cell disease, clinical trial design, and building strategic partnerships, among others.
“This meeting provided a wonderful opportunity to foster discussions between communities that are integral in translating research ideas and bringing new discoveries to those affected by sickle cell disease,” said Dr. Thackray. “We were honored to share our perspective on challenges, as well as opportunities, related to the conduct of clinical studies like the Phase 2 trial we conducted of GMI-1070, a novel potential therapy for the treatment of vaso-occlusive crisis (VOC) in sickle cell disease.”
The randomized, double-blinded Phase 2 clinical trial, which formed the basis for the presentation, examined the safety, efficacy, and pharmacokinetics of GMI-1070 in hospitalized sickle cell patients experiencing VOC. The trial, which enrolled 76 patients ranging from 12 to 60 years old at 22 trial sites in
For more information on the research meeting, visit: http://www.cvent.com/events/annual-sickle-cell-disease-clinical-research-meetings/event-summary-b0cafc512d25422096ef3a6a28095937.aspx.
GlycoMimetics is a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using its expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of glycomimetic drug candidates that inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection. For additional information, please visit the company’s web site at http://www.glycomimetics.com.
About Sickle Cell Disease and VOC
Sickle cell disease is a genetic disease affecting 90,000 to 100,000 people in